

INCOME STATEMENT
Year ended 31st December 2006

	2006 £m	2005 £m	Growth CER%	Growth £%
Turnover:				
Pharmaceuticals	20,078	18,661	9	8
Consumer Healthcare	3,147	2,999	6	5
TURNOVER	23,225	21,660	9	7
Cost of sales	(5,010)	(4,764)	6	5
Gross profit	18,215	16,896	9	8
Selling, general and administration	(7,257)	(7,250)	-	-
Research and development	(3,457)	(3,136)	11	10
Other operating income	307	364		
Operating profit:				
Pharmaceuticals	7,125	6,159	19	16
Consumer Healthcare	683	715	(3)	(4)
OPERATING PROFIT	7,808	6,874	17	14
Finance income	287	257		
Finance expense	(352)	(451)		
Share of after tax profits of associates and joint ventures	56	52		
PROFIT BEFORE TAXATION	7,799	6,732	19	16
Taxation (includes overseas tax of £1,912 million (2005: £1,826 million) <i>Tax rate %</i>	(2,301) 29.5%	(1,916) 28.5%		
PROFIT AFTER TAXATION FOR THE YEAR	5,498	4,816	17	14
Profit attributable to minority interests	109	127		
Profit attributable to shareholders	5,389	4,689		
	5,498	4,816		
EARNINGS PER SHARE	95.5p	82.6p	19	16
Diluted earnings per share	94.5p	82.0p		

INCOME STATEMENT
Three months ended 31st December 2006

	Q4 2006 £m	Q4 2005 £m	Growth CER%	Growth £%
Turnover:				
Pharmaceuticals	5,136	5,108	8	1
Consumer Healthcare	823	799	9	3
TURNOVER	5,959	5,907	9	1
Cost of sales	(1,445)	(1,298)	15	11
Gross profit	4,514	4,609	7	2
Selling, general and administration	(1,934)	(2,040)	-	(5)
Research and development	(980)	(968)	6	1
Other operating income	100	32		
Operating profit:				
Pharmaceuticals	1,501	1,440	21	4
Consumer Healthcare	199	193	8	3
OPERATING PROFIT	1,700	1,633	19	4
Finance income	83	85		
Finance expense	(86)	(125)		
Share of after tax profits of associates and joint ventures	13	13		
PROFIT BEFORE TAXATION	1,710	1,606	22	6
Taxation	(505)	(455)		
<i>Tax rate %</i>	29.5%	28.3%		
PROFIT AFTER TAXATION FOR THE PERIOD	1,205	1,151	20	5
Profit attributable to minority interests	24	29		
Profit attributable to shareholders	1,181	1,122		
	1,205	1,151		
EARNINGS PER SHARE	21.0p	19.8p	22	6
Diluted earnings per share	20.8p	19.6p		

PHARMACEUTICAL TURNOVER
Year ended 31st December 2006

	Total			USA			Europe			International		
	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%
RESPIRATORY	4,995	-	(1)	2,461	(3)	(5)	1,697	3	2	837	4	3
<i>Seretide/Advair</i>	3,313	11	10	1,870	13	11	1,133	10	10	310	9	10
<i>Flixotide/Flovent</i>	659	5	3	298	16	14	173	(8)	(8)	188	2	-
<i>Serevent</i>	291	(10)	(12)	86	(16)	(17)	140	(13)	(13)	65	5	(2)
<i>Flixonase/Flonase</i>	311	(52)	(53)	184	(63)	(64)	51	(15)	(15)	76	(14)	(16)
CENTRAL NERVOUS SYSTEM	3,642	15	13	2,588	28	26	595	(15)	15	459	2	(1)
<i>Seroxat/Paxil</i>	620	4	1	175	35	32	149	(20)	(20)	296	5	-
<i>Paxil IR</i>	448	(5)	(8)	19	11	6	149	(20)	(20)	280	4	(1)
<i>Paxil CR</i>	172	37	35	156	38	36	-	-	-	16	25	33
<i>Wellbutrin</i>	900	24	22	882	24	22	2	-	-	16	7	14
<i>Wellbutrin IR, SR</i>	102	12	11	89	14	11	2	-	-	11	-	10
<i>Wellbutrin XL</i>	798	25	23	793	25	23	-	-	-	5	25	25
<i>Imigran/Imitrex</i>	711	3	2	551	11	9	118	(18)	(18)	42	(12)	(14)
<i>Lamictal</i>	996	19	17	765	37	35	175	(22)	(23)	56	2	2
<i>Requip</i>	268	74	72	176	>100	>100	81	21	19	11	25	38
ANTI-VIRALS	2,827	10	9	1,354	7	5	855	11	11	618	16	14
HIV	1,515	(1)	(3)	700	(7)	(9)	621	3	2	194	8	7
<i>Combivir</i>	528	(9)	(9)	238	(14)	(16)	217	(4)	(4)	73	-	-
<i>Trizivir</i>	268	(11)	(12)	141	(13)	(15)	113	(7)	(8)	14	(7)	-
<i>Epivir</i>	202	(21)	(23)	69	(25)	(26)	90	(26)	(26)	43	(2)	(7)
<i>Ziagen</i>	117	(13)	(14)	48	(11)	(13)	41	(24)	(24)	28	4	4
<i>Agenerase, Lexiva</i>	131	18	17	74	7	6	48	40	37	9	14	29
<i>Epzicom/Kivexa</i>	241	>100	>100	125	49	47	97	>100	>100	19	>100	>100
Herpes	965	19	17	610	30	28	144	4	4	211	3	-
<i>Valtrex</i>	845	24	22	600	30	28	109	12	11	136	10	7
<i>Zovirax</i>	120	(6)	(8)	10	67	67	35	(15)	(15)	75	(7)	(11)
<i>Zeffix</i>	162	12	12	13	8	8	23	10	10	126	13	13
<i>Relenza</i>	91	>100	>100	-	-	-	62	>100	>100	29	>100	>100
METABOLIC	1,875	27	25	1,277	30	28	252	33	33	346	12	12
<i>Avandia</i>	1,399	23	21	1,068	26	24	125	13	12	206	13	16
<i>Avandamet</i>	204	17	17-	86	(22)	(24)	92	>100	>100	26	41	53
<i>Avandaryl</i>	42	-	-	40	-	-	-	-	-	2	-	-
<i>Bonviva/Boniva</i>	95	>100	>100	83	>100	>100	12	>100	>100	-	-	-
VACCINES	1,692	23	22	465	40	38	709	20	20	518	13	13
<i>Hepatitis</i>	479	9	8	161	21	18	227	2	2	91	8	10
<i>Infanrix/Pediarix</i>	511	29	28	172	20	18	281	40	39	58	12	12
<i>Boostrix</i>	60	>100	>100	41	>100	>100	15	88	88	4	67	33
CARDIOVASCULAR AND UROGENITAL	1,636	24	23	1,072	42	40	395	(4)	(5)	169	13	13
<i>Coreg</i>	779	38	36	773	38	36	-	-	-	6	20	20
<i>Levitra</i>	43	8	8	41	20	17	1	(75)	(75)	1	(100)	-
<i>Avodart</i>	216	69	67	131	>100	>100	69	25	25	16	67	78
<i>Arixtra</i>	58	>100	>100	32	>100	>100	23	>100	>100	3	>100	>100
<i>Fraxiparine</i>	209	(1)	(1)	-	-	-	179	-	-	30	(6)	(6)
ANTI-BACTERIALS	1,369	(9)	(10)	217	(15)	(17)	628	(12)	(13)	524	(2)	(3)
<i>Augmentin</i>	570	(14)	(14)	94	(31)	(32)	268	(15)	(15)	208	-	(1)
<i>Zinnat/Ceftin</i>	164	(16)	(17)	12	20	20	82	(27)	(27)	70	(5)	(7)
ONCOLOGY AND EMESIS	1,069	7	5	836	12	10	153	(7)	(7)	80	(11)	(12)
<i>Zofran</i>	847	3	1	679	8	6	107	(14)	(14)	61	(16)	(18)
<i>Hycamtin</i>	113	15	14	72	11	9	34	26	26	7	17	17
OTHER	973	(5)	(6)	83	19	19	263	(19)	(18)	627	(1)	(3)
<i>Zantac</i>	232	(2)	(5)	72	28	24	52	(19)	(19)	108	(7)	(11)
	20,078	9	8	10,353	16	14	5,547	1	-	4,178	6	4

Pharmaceutical turnover includes co-promotion income.

PHARMACEUTICAL TURNOVER
Three months ended 31st December 2006

	Total			USA			Europe			International		
	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%
RESPIRATORY	1,269	(3)	(10)	616	(7)	(16)	433	1	(1)	220	-	(8)
<i>Seretide/Advair</i>	862	9	1	493	11	-	293	8	6	76	1	(6)
<i>Flixotide/Flovent</i>	172	7	(1)	79	22	10	42	(12)	(14)	51	4	(4)
<i>Serevent</i>	74	(9)	(15)	22	(17)	(24)	33	(13)	(15)	19	11	-
<i>Flixonase/Flonase</i>	48	(69)	(72)	17	(85)	(87)	11	(15)	(15)	20	(8)	(17)
CENTRAL NERVOUS SYSTEM	915	13	3	660	25	13	137	(17)	(18)	118	(3)	(11)
<i>Seroxat/Paxil</i>	163	11	3	49	72	53	35	(10)	(13)	79	(1)	(8)
<i>Paxil IR</i>	113	-	(7)	3	-	-	35	(10)	(13)	75	-	(9)
<i>Paxil CR</i>	50	50	39	46	59	44	-	-	-	4	(25)	-
<i>Wellbutrin</i>	212	9	(2)	208	10	(2)	-	-	-	4	(25)	-
<i>Wellbutrin IR, SR</i>	25	13	4	22	25	10	-	-	-	3	(33)	-
<i>Wellbutrin XL</i>	187	9	(3)	186	9	(3)	-	-	-	1	-	-
<i>Imigran/Imitrex</i>	174	2	(7)	138	12	-	25	(34)	(34)	11	-	(8)
<i>Lamictal</i>	257	23	13	204	39	25	39	(22)	(24)	14	-	-
<i>Requip</i>	76	62	52	52	97	79	21	16	11	3	-	50
ANTI-VIRALS	706	9	1	333	8	(4)	210	11	9	163	11	4
HIV	360	(5)	(11)	168	(7)	(17)	146	(3)	(5)	45	2	(6)
<i>Combivir</i>	119	(14)	(20)	56	(15)	(24)	48	(9)	(11)	15	(20)	(25)
<i>Trizivir</i>	61	(14)	(21)	32	(16)	(27)	25	(13)	(17)	4	-	33
<i>Eпивir</i>	43	(24)	(31)	15	(23)	(32)	18	(34)	(38)	10	-	(9)
<i>Ziagen</i>	28	(12)	(18)	12	(7)	(14)	10	(9)	(9)	6	(22)	(33)
<i>Agenerase, Lexiva</i>	34	12	3	19	5	(5)	12	18	9	3	50	50
<i>Epzicom/Kivexa</i>	69	66	57	33	29	18	29	100	93	7	>100	>100
Herpes	242	18	8	154	30	17	36	9	6	52	(5)	(10)
<i>Valtrex</i>	212	23	12	150	28	15	27	17	13	35	6	-
<i>Zovirax</i>	30	(9)	(12)	4	>100	>100	9	(10)	(10)	17	(22)	(26)
<i>Zeffix</i>	42	5	-	3	33	-	6	-	-	33	3	-
<i>Relenza</i>	37	>100	>100	-	-	-	22	>100	>100	15	>100	>100
METABOLIC	474	34	22	321	45	30	69	27	25	84	7	(2)
<i>Avandia</i>	324	25	12	246	32	17	30	7	3	48	4	(4)
<i>Avandamet</i>	68	54	48	32	40	28	27	75	69	9	60	80
<i>Avandaryl</i>	14	-	-	14	-	-	-	-	-	-	-	-
<i>Bonviva/Boniva</i>	34	>100	>100	29	>100	>100	5	-	-	-	-	-
VACCINES	527	31	25	162	84	71	200	20	18	165	10	6
<i>Hepatitis</i>	128	19	14	43	38	26	60	11	11	25	8	4
<i>Infanrix/Pediarix</i>	136	29	21	47	37	24	72	36	31	17	(11)	(11)
<i>Boostrix</i>	18	73	64	13	63	63	5	67	67	-	-	-
CARDIOVASCULAR AND UROGENITAL	421	25	15	281	44	29	101	(1)	(4)	39	(9)	(11)
<i>Coreg</i>	199	39	25	198	39	25	-	-	-	1	-	-
<i>Levitra</i>	12	30	20	12	44	33	-	-	-	-	-	-
<i>Avodart</i>	61	67	56	36	95	71	19	27	27	6	67	100
<i>Arixtra</i>	21	>100	>100	12	>100	>100	7	>100	>100	2	-	-
<i>Fraxiparine</i>	53	(2)	(4)	-	-	-	44	(4)	(4)	9	11	-
ANTI-BACTERIALS	354	(8)	(13)	57	(15)	(22)	164	(9)	(11)	133	(3)	(10)
<i>Augmentin</i>	145	(11)	(15)	25	(20)	(29)	67	(15)	(17)	53	2	(2)
<i>Zinnat/Ceftin</i>	42	(19)	(22)	3	-	(25)	22	(24)	(24)	17	(14)	(19)
ONCOLOGY AND EMESIS	213	(11)	(21)	162	(10)	(22)	33	(15)	(15)	18	(20)	(28)
<i>Zofran</i>	165	(19)	(28)	130	(16)	(27)	21	(30)	(30)	14	(25)	(30)
<i>Hycamtin</i>	28	20	12	18	18	6	8	50	33	2	(50)	-
OTHER	257	2	(4)	18	5	(5)	80	(7)	(7)	159	6	(3)
<i>Zantac</i>	55	(5)	(14)	16	12	(6)	13	(24)	(24)	26	(3)	(13)
	5,136	8	1	2,610	15	4	1,427	1	(1)	1,099	3	(5)

Pharmaceutical turnover includes co-promotion income.

CONSUMER HEALTHCARE TURNOVER
Year ended 31st December 2006

	2006 £m	Growth CER%	£%
Over-the-counter medicines	1,496	5	4
Analgesics	380	7	5
Dermatological	165	4	2
Gastrointestinal	252	2	1
Respiratory tract	172	12	12
Smoking control	353	7	5
Natural wellness support	132	-	(1)
Oral care	993	6	5
Nutritional healthcare	658	7	6
Total	3,147	6	5

CONSUMER HEALTHCARE TURNOVER
Three months ended 31st December 2006

	Q4 2006 £m	Growth CER%	£%
Over-the-counter medicines	409	9	2
Analgesics	95	9	1
Dermatological	43	15	5
Gastrointestinal	63	3	(6)
Respiratory tract	54	8	6
Smoking control	103	18	10
Natural wellness support	38	11	6
Oral care	258	10	5
Nutritional healthcare	156	5	1
Total	823	9	3